1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Generic Name | Common Trade Name(s) | Classification | Date Marketed in Canada (yyyy/mm/dd) |
---|---|---|---|
Brigatinib | Alunbrig | Antineoplastic agent | 2018/07/26 |
Apalutamide | Erleada | Anti-androgen | 2018/07/27 |
Erenumab | Aimovig | Anti-calcitonin gene-related peptide receptor | 2018/08/01 |
Baricitinib | Olumiant | Immunosuppressant | 2018/08/17 |
Crisaborole | Eucrisa | PDE-4 inhibitor | 2018/08/29 |
Cabozantinib | Cabometyx | Antineoplastic agent | 2018/09/14 |
Telotristat ethyl | Xermelo | Tryptophan hydroxylase inhibitor | 2018/10/12 |
Elagolix | Orilissa | Gonadotropin releasing hormone receptor antagonist | 2018/10/31 |
Ivermectin | Stromectol | Anthelmintic | 2018/11/07 |
Doravirine | Pifeltro | NNRTI | 2018/11/15 |
Ribociclib | Kisqali | Antineoplastic agent | 2018/11/26 |
Burosumab | Crysvita | Fibroblast growth factor 23 (FGF23) Inhibitor | 2018/12/05 |
Doravirine + Lamivudine + Tenofovir | Delstrigo | Antiviral agent | 2018/12/15 |
Buprenorphine | Sublocade | Partial opioid agonist | 2019 |
Enasidenib | IDHIFA | Antineoplastic agent / IDH2 Inhibitor | 2019/02/27 |
Suvorexant | Belsomra | Hypnotic | 2019/04/16 |
Lorlatinib | Lorbrena | Tyrosine kinase inhibitor | 2019/04/22 |
Dacomitinib | Vizimpro | Tyrosine kinase inhibitor | 2019/04/22 |
Risankizumab | Skyrizi | Interleukin-23 inihbitor | 2019/05/13 |
Cemiplimab | Libtayo | Antineoplastic agent | 2019/05/24 |
Abemaciclib | Verzenio | Protein kinase inhibitor | 2019/07/03 |
Safinamide | Onstryv | Monoamine oxidase B inhibitor | 2019/07/10 |
Larotrectinib | Vitrakvi | Antineoplastic agent | 2019/07/10 |
Romosozumab | Evenity | Bone formation agent | 2019/08/12 |
Galcanezumab | Emgality | CGRP binding antibody | 2019/10/02 |
Sodium zirconium cyclosilicate | Lokelma | Potassium binder | 2019/10/17 |
Edaravone | Radicava | Treatment for amyotrophic lateral sclerosis | 2019/10/29 |
Glucagon | Baqsimi | Hyperglycemic agent | 2019/11/20 |
Axicabtagene ciloleucel | Yescarta | Antineoplastic agent | 2019/11/27 |
Erdafitinib | Balversa | Protein kinase inhibitor | 2019/12/09 |
Niraparib | Zejula | Antineoplastic agent | 2020/01/09 |
Upadacitinib | Rinvoq | Disease-modifying antirheumatic agent | 2020/01/16 |
Prasugrel | Effient | Antiplatelet agent | 2020/01/31 |
Gilteritinib | Xospata | Antineoplastic agent | 2020/02/03 |
Baloxavir marboxil | Xofluza | Antiviral agent | 2020/02/19 |
Patiromer | Veltassa | Potassium binder | 2020/03/09 |